We discuss the most impactful health policy and healthcare finances developments shaping the US Healthcare system now and in the future. We also discuss personal development for physician executives. Co-hosts Dr Anthony Paravati and Dr Amar Rewari.
Paying More, Getting Less: Joel White's Five Fixes for America's Broken Health Care Market
American families now spend roughly one fifth of their income on health premiums, and if current trends hold, that number could reach 40 percent by 2032. In this episode of Value Health Voices, Dr. Amar Rewari and Dr. Anthony Paravati sit down with Joel White, president of the Council for Affordable Health Coverage and former staff director of the House Ways and Means Health Subcommittee, to understand why the system keeps charging more while delivering narrower networks, higher cost sharing, and more prior authorization friction.
Joel argues that the United States does not have a free market in health care at all, but a system of localized monopolies shaped by regulation. He walks through how the medical loss ratio rule became a consolidation engine for vertically integrated insurers, how 340B drifted from a safety net program into what he calls a scam that never reaches the patient, and why pharmacy benefit managers capture roughly half of every dollar spent on drugs. Along the way, he explains what the PBM law signed earlier this year actually changes, why CMS is pushing site neutral payment into imaging, and why he believes fee-for-service medicine is a relic that should be retired.
The conversation closes with Joel's five pillar agenda for affordability: real price and quality transparency, giving consumers the freedom to choose any approved plan, sending subsidies to people instead of insurers, driving down underlying medical costs through simpler value-based models, and restoring competitive markets through antitrust enforcement and more independent practice. Whether you lead a health system, run a practice, or simply pay a premium every month, this episode offers a clear map of the reforms that could reshape what care costs in the next few years.
Resources:
【Council for Affordable Health Coverage Policy Priorities (https://cahc.net/policy-priorities/)】
【Patients Deserve Price Tags Act (S.3548) (https://www.congress.gov/bill/119th-congress/senate-bill/2355)】
【Association Health Plans Act (H.R. 2868) (https://www.congress.gov/bill/119th-congress/house-bill/2528)】
【LinkedIn (https://www.linkedin.com/company/value-health-voices)】
【Instagram (https://www.instagram.com/valuehealthvoices/)】
【TikTok (https://www.tiktok.com/@valuehealthvoices)】
【Newsletter (https://www.valuehealthvoices.com/newsletter)】
【Apple Podcasts (https://podcasts.apple.com/us/podcast/value-health-voices/id1777493904)】
【Spotify (https://open.spotify.com/show/0cxnf4Il3QK3cvFFKxwPWL?si=8bb96d2547b2495b&nd=1&dlsi=4538b3c9fb694f00)】
3 Sept 2026
Dr. Zeke Emanuel: The ACA's Fatal Flaw, Junking 340B, and Why AI Will Outperform Doctors
Dr. Ezekiel "Zeke" Emanuel helped design the Affordable Care Act, and 16 years later he has a surprising answer to what he would change: the law made an already impossible system even more complicated. In this episode of Value Health Voices, Drs. Anthony Paravati and Amar Rewari sit down with the oncologist, medical ethicist, and University of Pennsylvania professor for a wide-ranging conversation on what the ACA got right, what it got wrong, and why he believes the next wave of reform has to be built on three mantras: simplification, standardization, and digitization.
From there the conversation runs through the greatest hits of health policy frustration. Zeke explains why the IRA drug negotiations were not the home run the country needed, how the biologic and small molecule patent protection timelines quietly bias the market toward more expensive drugs, and why he would scrap 340B entirely in favor of direct subsidies and a tax on manufacturers. The three physicians also dig into the RUC and physician fee schedule, radiation oncology's failed bundled payment experiment and the new ROCR proposal, percentage-based reimbursement for drugs that have driven up drug prices, and the growing evidence that private equity has yet to improve cost or quality anywhere in medicine.
The episode closes with two of Zeke's most provocative arguments. Drawing on his new JAMA review of more than 100 studies, he makes the case that autonomous AI already matches or beats physicians in six core clinical areas, and that keeping a doctor in the loop will eventually degrade care rather than improve it. Then he turns personal, sharing which rule from his book Eat Your Ice Cream doctors most overlook and explaining why, more than a decade after writing "Why I Hope to Die at 75," his number has not moved.
Resources:
【Dr. Ezekiel Emanuel Website (https://www.ezekielemanuel.com/)】
【"Eat Your Ice Cream" By. Dr. Emanuel (https://wwnorton.com/books/9781324117537)】
【LinkedIn (https://www.linkedin.com/company/value-health-voices)】
【Instagram (https://www.instagram.com/valuehealthvoices/)】
【TikTok (https://www.tiktok.com/@valuehealthvoices)】
【Newsletter (https://www.valuehealthvoices.com/newsletter)】
【Apple Podcasts (https://podcasts.apple.com/us/podcast/value-health-voices/id1777493904)】
【Spotify (https://open.spotify.com/show/0cxnf4Il3QK3cvFFKxwPWL?si=8bb96d2547b2495b&nd=1&dlsi=4538b3c9fb694f00)】
20 Aug 2026
Mark Cuban: Why You're Overpaying for Prescriptions – and Who's Pocketing the Difference
Mark Cuban did not set out to become the most disruptive force in American drug pricing. He just wanted to know why the same generic pill could cost $15 at one pharmacy and $500 at another. In this episode of Value Health Voices, Mark tells Dr. Anthony Paravati and Dr. Amar Rewari exactly what he found when he peered under the hood of the pharmacy supply chain, and why his answer was to launch Cost Plus Drugs with a radically simple promise: show patients the real cost, add a fair markup, and sell trust instead of marketing.
The conversation goes deep into the machinery most patients never see. Mark breaks down how pharmacy benefit managers profit from rebates, spread pricing, and formulary threats, why brand manufacturers privately admit they cannot work with him, and how vertically integrated conglomerates shuffle billions between their own subsidiaries. He shares the story of a heart transplant patient whose life depended on a $200 generic her employer's plan refused to cover, and explains why he now spends his time telling CEOs to run their PBM contracts through AI and ask one question: where am I getting ripped off?
Mark also lays out his blueprint for reform, including deductible credit for cash purchases, real consequences for repeat offenders, federally guaranteed healthcare loans, and full contract transparency. He makes the case for direct contracting between hospitals and self-insured employers, explains why he believes real change comes from outside Washington, and settles the question everyone keeps asking: whether he will run for president. This is a candid, unfiltered look at the business of American healthcare from the one outsider who decided to fix it himself.
Episode Resources:
Mark Cuban’s Cost Plus Drug Company (https://costplusdrugs.com/)
Cost Plus Wellness for Self-Insured Employers (https://costpluswellness.com/)
JAMA Study on Potential Savings via Cost Plus Drugs (https://jamanetwork.com/journals/jama-health-forum/fullarticle/2819897)
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
YouTube views
41,124
Score snapshot 15 Sept 2025
Apple Podcasts (US)
5.0 / 5
5 ratings
Spotify
4.9 / 5
21 ratings
Podcast Authority Score: 45 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
40
Social presence
0
YouTube
76
Engagement
51
Contact Value Health Voices
Guest appearances
Does not typically book guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
